tirzepatide sleep apnea fda approval GLP-1 medication is known to improve apnea, but not all patients benefit equally. In a new study, presented at #ATS2026, Scott Sands, PhD, associate professor of medicine at Brigham and FDA's First GLP-1 Approval for

The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease

Specific situations warrant urgent professional dietary consultation: Unintentional excessive weight loss losing more than 1 kg weekly consistently, or experiencing rapid weight loss that feels uncontrolled Inability to meet minimum calorie requirements due to severe appetite suppression, nausea, or other side effects Signs of nutritional deficiency , including unusual fatigue, weakness, hair loss, brittle nails, frequent infections, or poor wound healing Pre-existing eating disorders or disordered eating patterns, as GLP-1 medications may complicate these conditions Complex medical conditions such as chronic kidney disease, liver disease, or malabsorption disorders requiring specialised dietary management Pregnancy or breastfeeding GLP-1 medications should not be used during pregnancy

[1] [2] These results have generated considerable interest within the obesity medicine community

Given the immunosuppressive features of cannabis smoke on lung macrophages, a similar response could occur, although more research is needed to understand the impact of cannabis smoke and cannabinoids on macrophage efferocytosis and whether such changes are beneficial or detrimental

These effects contribute to blood sugar control in individuals with type 2 diabetes and can also lead to weight loss by reducing appetite and increasing satiety

Many Cigna plans in Florida include telehealth benefits for weight management consultations